background image

Who is Wilmington Pharmaceuticals?

Taking proven medicines and providing improved delivery

From our corporate headquarters in Wilmington, North Carolina, we have a brilliant vantage point to engage the ever-changing pharmaceutical environment. We are able to gain a valuable perspective on where the industry has been, where it is, and where it’s heading.

We develop patient-friendly, fast-dissolving formulations for established medicines with an unmet patient need for simpler, more reliable dosage forms. Applying commercially proven fast-dissolve delivery technologies to established medicines allows for rapid product development and commercialization.

Because we’re an independent development company, we’re flexible enough to deliver rapid commercialization. Our best minds are constantly in tune with your business and not preoccupied with hierarchies or focused on any sales force other than our licensing partners—this creates an optimized environment for effective decisions.

At Wilmington Pharmaceuticals, we have a senior management team that is focused on profitable growth strategies.

dotted line

Eugene T. Haley, Cheif Executive Officer and FounderEugene T. Haley

Chief Executive Officer and Founder

Gene brings more than 35 years of experience in developing corporate strategies, driving business in high-growth environments and creatively building value through the development of strategic partnerships and acquisitions. He has held leadership positions at AAIPharma, Eastman Kodak’s imaging subsidiary Qualex Inc, and Fuqua Industries. His key positions held include International Managing Director, Chief Financial Officer and Executive Vice President of Global Marketing and Sales. Gene is active in the North Carolina entrepreneurial community and is a member of the North Carolina Small Business & Technology Development Center Board of Advisors, a member of the Biotech Advisory Committee of Southeastern North Carolina and a member of the University of North Carolina Wilmington Cameron Executive Network. Gene holds a degree in Accounting from the University of Georgia.

Thomas J. Aluise, Chief Financial OfficerThomas J. Aluise

Chief Financial Officer

Tom is a senior financial professional bringing more than 35 years of experience in consumer products, pharmaceuticals and pharmaceutical development to the table. He has held key positions with Merck’s Calgon subsidiary, Beecham Inc, Qualex Inc and AAIPharma. In addition to his financial and risk management background, Tom has extensive experience in the execution and creation of strategic business plans. Tom’s education includes a BA in Economics and Business as well as formal leadership and financial instrument training.

David A. Burns R.Ph., Vice President, Development and ManufacturingDavid A. Burns R.Ph.

Vice President, Development and Manufacturing

Dave has over 20 years’ experience in the pharmaceutical industry. He is an industry professional with an extensive background in specialty pharmaceutical companies. He has worked in manufacturing management, technology transfer, technical services, and business development for AAIPharma. He has held roles in technical services, manufacturing management and technology transfer at Roxane Laboratories, a division of Boehringer Ingelheim, and as a research scientist for Duramed Pharmaceuticals and KV Pharmaceuticals. He is an expert in commercial development and scale-up and is also a registered pharmacist. He has a degree in Pharmacy from Purdue University and extensive coursework in chemical engineering.

dotted line

We have created a network of dedicated professionals who deliver value to partners in a changing pharmaceutical landscape. Our virtually integrated pharma company (VIPCO) helps companies reduce costs, increase predictability and compress commercialization timelines.

Wilmington Pharmaceuticals Virtually Integrated Network Wilmington Pharmaceuticals Virtually Integrated Network

Reference: 1. Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system for famotidine. J Clin Pharmacol. 1995;35:362-367.

Zydis® is a registered trademark of Catalent Pharma Solutions.

dotted line

Reliablility“The Zydis® fast-dissolve technology is far and away the most commercially successful in the industry. Wiith over 15 FDA-approved Zydis® products, the resulting extensive regulatory and commercial experience leads to a rapid and highly dependable development and manufacturing program.”David A. Burns, Vice President, Development and Manufacturing

dotted line

75% of patients expressed a preference for
the fast-dissolve formulation compared with a tablet.1
Click here to learn more.